Approximation error

Orbis and Alcon to Kick Off Two-Week Training for Caribbean Eye Care Teams to Help Fight Avoidable Blindness in Local Communities

Retrieved on: 
Thursday, August 4, 2022 - 9:35pm

FORT WORTH, Texas, Aug. 4, 2022 /PRNewswire/ -- On Monday, August 8, Orbis International, with generous support from Alcon, the global leader in eye care, will kick off its first in-person training project on board the Flying Eye Hospital – a fully accredited ophthalmic teaching hospital on board a plane – since the pandemic began. Over a two-week period, Orbis's clinical staff and Volunteer Faculty (medical experts) along with Alcon bioengineers and trainers will share their knowledge with nearly 50 ophthalmologists, ophthalmology residents, nurses and biomedical engineers from several countries throughout the Caribbean,1 helping them build skills to fight avoidable blindness in their communities.

Key Points: 
  • Simulation training allows the visiting eye care teams to grow their confidence in a training environment before moving on to real-life surgical procedures.
  • Since 1982, three generations of the Flying Eye Hospital have taken training to eye care teams in over 95 countries around the world.
  • In 2020, Orbis reimagined in-person Flying Eye Hospital trainings as virtual ones to ensure that eye care teams could still access critical training safely during the pandemic.
  • Our more than 24,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care.

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022 - 2:16am

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.

Vigil Neuroscience Presents Preclinical Data on VGL101 for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) and Clinical Phenotype of ALSP at Alzheimer's Association International Conference 2022

Retrieved on: 
Monday, August 1, 2022 - 12:00pm

Importantly, ALSP is commonly misdiagnosed as a neurodegenerative dementia and in the presence of family history and radiological findings physicians should consider genetic testing for ALSP.

Key Points: 
  • Importantly, ALSP is commonly misdiagnosed as a neurodegenerative dementia and in the presence of family history and radiological findings physicians should consider genetic testing for ALSP.
  • VGL101 administration induced phosphorylation of SYK in both hMDM and iMGL models, demonstrating agonism of the TREM2 receptor.
  • Increases in soluble CSF1R and decreases in soluble TREM2 upon VGL101 administration in iMGLs may inform target engagement studies.
  • The findings of this study supported and expanded the previous, smaller case reports on the phenotypic characteristics of ALSP.

Magnolia Medical Technologies Wins Patent-Infringement Lawsuit against Kurin, Inc.

Retrieved on: 
Friday, July 29, 2022 - 2:30pm

SEATTLE, July 29, 2022 /PRNewswire/ -- A jury for the U.S. District Court of Delaware delivered two unanimous verdicts this week in favor of Magnolia Medical Technologies, Inc. ("Magnolia Medical") in a lawsuit against Kurin, Inc., ("Kurin") regarding the unlawful use of its innovative Initial Specimen Diversion Device® (ISDD®) technology. After a two-phased trial and short deliberations, the jury confirmed that Kurin has used Magnolia Medical's patented technology, which is clinically proven to significantly reduce blood culture contamination, without the company's permission. The jury also validated Magnolia Medical's patented technology and awarded significant damages in their final verdict.

Key Points: 
  • "Magnolia Medical Technologies is gratified by the jury's unanimous verdicts in our favor this week, finding that Kurin, Inc. unlawfully used our innovative technology without permission," said Magnolia Medical's CEO and Co-Founder Greg Bullington.
  • Bullington concluded, "Magnolia Medical is deeply committed to our Mission toZERO, with the goal of eliminating sepsis misdiagnosis.
  • Magnolia Medical Technologies develops, manufactures, and markets innovative blood and bodily fluid collection devices to facilitate significant improvements in the accuracy, consistency, and predictability of critical laboratory tests.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Initial Specimen Diversion Device (ISDD) for blood culture collection and contamination prevention.

Laboratory Industry Doesn't Forget COVID-19, But Shifts Focus to Other Health Conditions at AACC 2022 in Chicago

Retrieved on: 
Thursday, July 28, 2022 - 12:00pm

CHICAGO, July 28, 2022 /PRNewswire/ -- Urgent healthcare problems were addressed at the 2022 American Association for Clinical Chemistry (AACC) meeting of lab professionals and IVD vendors in Chicago.

Key Points: 
  • CHICAGO, July 28, 2022 /PRNewswire/ -- Urgent healthcare problems were addressed at the 2022 American Association for Clinical Chemistry (AACC) meeting of lab professionals and IVD vendors in Chicago.
  • Kalorama Information analysts attended sessions and observed trends at the AACC meeting, noting that very little focus was related to the recent pandemic.
  • Perhaps a vestige of the COVID-19 pandemic was a focus on better and faster workflows, automation and other products.
  • AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes' trial, moderated the discussion.

Latin America Pharmacy Automation Equipment Market 2022-2028: Growing Preference For Decentralized Pharmacy Services & Surging Demand For Specialty Drugs Contributing to Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 27, 2022 - 5:16pm

The "Latin America Pharmacy Automation Equipment Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Latin America Pharmacy Automation Equipment Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The publisher's report estimates that the pharmacy automation equipment market in Latin America will advance at a CAGR of 6.88% during the assessed years of 2022-2028.
  • In Mexico, the rising medical tourism offers several medical services to patients, influencing the growth of the studied market.
  • Hence, the rise in medical errors and growing awareness about these errors is expected to widen the growth of the pharmacy automation equipment market.

Global Medication Management System Market Report 2022-2030: Key Players Becton, Dickinson and Company, GE Healthcare, McKesson & Others Driving 11.2% Annual Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 26, 2022 - 12:33pm

The global medication management system market size is expected to reach USD 6.3 billion by 2030.

Key Points: 
  • The global medication management system market size is expected to reach USD 6.3 billion by 2030.
  • Rapid growth in prescriptions has increased the burden on care providers to efficiently manage prescriptions of patients and minimize medication errors.
  • Thus, increase in the number of prescriptions is one crucial factor driving the market growth.
  • For instance, the German National Medication Plan is an initiative directed toward enhancing medication management software in hospitals and pharmacies in Germany.

Intravenous Infusion Pumps Global Market Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 26, 2022 - 11:38am

The "Intravenous Infusion Pumps Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intravenous Infusion Pumps Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The intravenous infusion pumps market consists of sales of intravenous infusion pumps and related services by entities (organizations, sole traders, and partnerships) that manufacture intravenous infusion pumps.
  • The high cost of intravenous infusion pumps is a key factor hampering the growth of the intravenous infusion pumps market.
  • Therefore, the high cost of intravenous infusion pumps, which increases the cost of drug therapies, is expected to hinder the market growth for intravenous infusion pumps.

HealthTrust Performance GroupSM Honors Members for Excellence, Sustainability and Innovation

Retrieved on: 
Tuesday, July 26, 2022 - 11:00am

Six HealthTrust member organizations have been singled out for supply chain excellence, sustainability and innovation benefitting their patients, communities and stakeholders.

Key Points: 
  • Six HealthTrust member organizations have been singled out for supply chain excellence, sustainability and innovation benefitting their patients, communities and stakeholders.
  • Recipients of the annual Member Recognition Awards the most prestigious honors presented by HealthTrust Performance Group were announced last evening at HealthTrust University conference in Nashville.
  • David Osborn, Ph.D., senior vice president of strategic accounts and advisory services presented awards to the following health systems and their representatives.
  • HealthTrust (HealthTrust Purchasing Group, L.P.) is committed to strengthening provider performance and clinical excellence through an aligned membership model and the delivery of total spend management advisory solutions that leverage our operator experience, scale and innovation.

World Clinical Decision Support System Market Report 2022: CDSS Emerged as a Key Tool to Fight Against Covid-19, Opening Up New Application Areas - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 26, 2022 - 10:02am

The global clinical decision support system market is forecast to grow at a compound annually growth rate of 10.5% during the forecast period 2022-2030.

Key Points: 
  • The global clinical decision support system market is forecast to grow at a compound annually growth rate of 10.5% during the forecast period 2022-2030.
  • CDSS Emerged as a Key Tool to Fight Against Covid-19, Opening Up New Application Areas
    CDSS has played a pivotal role in the fight against COVID-19.
  • What are the key micro and macro environmental factors that are impacting the growth of clinical decision support system market?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the clinical decision support system market worldwide?